Biologic Lyophilization Patents: Top Companies & Trends 2026
Biologic Lyophilization Freezing Control Patents: Who Leads and Where the Gaps Sit
Leadership is thin at the top. the top 5 assignees combined hold only 10.7% of the 6,636 records in scope, and the top 10 just 17.7% — a long tail dominates this field. Annual filings climbed to 346 in 2017 and peaked at 411 in 2018. From 2021 to 2024 — the last year that can be treated as complete — filings fell from 269 to 126, a 53% decline; 2025 and 2026 counts will continue to fill in as later-filed applications publish.
- 1AMGEN INC2.7%
- 2TAKEDA PHARMA CO LTD2.2%
- 3OTSUKA PHARM CO LTD1.9%
- 4PFIZER INC1.9%
- 5FERRING BV1.9%
See the full biologic lyophilization freezing control analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in biologic lyophilization freezing control?
The assignee ranking covers 100 companies, with the top-ranked filer holding 180 records and fifth place holding 125. However, the top 5 assignees combined account for only 10.7% of the 6,636 records in scope, so no single company controls the field. Practical competitive tracking should include the mid-tier filers ranked between fifth and tenth place, not just the single leader.
Is patent filing in freeze-drying process control increasing or slowing down?
Filings rose through the late 2010s to a peak of 411 in 2018, then declined from 269 in 2021 to 126 in 2024, a 53% drop over that three-year span. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so the most recent years understate real activity. Treat the 2021-2024 decline, not the raw 2025-2026 numbers, as the reliable trend signal.
What does US8800162B2 actually cover?
US8800162B2, assigned to Syntegon Telstar Technologies, claims a method for monitoring and controlling a freeze-drying process by isolating the drying chamber, collecting pressure and shelf-temperature readings during primary drying, and calculating a process parameter from those readings. It is a process-control patent focused on in-cycle measurement and calculation rather than on a specific biologic formulation. Anyone building automated shelf-temperature or chamber-pressure control logic for primary drying should review its claim scope directly.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Biologic Lyophilization Freezing Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.